Combinations of treatments based on radiotherapy or radionuclides to enhance immunotherapy efficacy in advanced prostate cancer: a systematic review
Journal of Cancer Research and Clinical Oncology · 2025
DOI: 10.1007/s00432-025-06245-3 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2025. Verfasst von Roberto Rosenfeld und 9 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine In Senology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy. Hauptthemen laut MEDLINE: Immunotherapy, Prostatic Neoplasms, Radioisotopes. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: This research has been partially supported by the Italian Ministry of Health Ricerca Corrente 2025..
Abstract (Originalsprache)
BACKGROUND: Prostate cancer (PCa) has been considered an immunologically "cold tumor". Indeed, in advanced PCa, immune checkpoint inhibitors (ICIs) or anti-tumor vaccines have shown poor results in phase II and phase III trials with the exception of sipuleucel-T that showed a modest survival benefit. Radiotherapy and Targeted radioisotopes, such as 223Radium or 177Lu-PSMA-617 monotherapy, contributed in prolonging the progression-free survival of PCa patients in second or third line. However, potential benefits of combination with immune therapies were inconstantly investigated and outcomes often were discordant. OBJECTIVE: Aim of this systematic review was to gather and analyze clinical evidence about benefits and risks of combining ionizing-radiation-based treatments with the main immunotherapies administed in clinical and experimental oncology for the setting of metastatic PCa. METHODS: We performed a systematic review according to the PRISMA-ScR criteria, investigating PubMed, Web of science, Embase and Medline databases from February 2000 to April 2024, searching for phase I to phase III clinical trials associating radiotherapy with immunotherapy (RT/IT) in metastatic PCa patients. CONCLUSION: We observed that combination of Ipilimumab with stereotactic beam radiotherapy (SBRT) at the dose of 8 Gy performed about 12 days (range 2-21) before immunotherapy was liked with trials with a significative gain in progression-free survival. Furtherly, we described better objective responses when immunotherapies, were associated with SBRT than radionuclides An exception was 177Lu-PSMA-617, which showed promising synergic results after few cycles of standard doses, suggesting a possible enhancing of immune system, in particular when associated with anti-PD1 (pembrolizumab). Due to the few data reported in literature, both for radiotherapy and radionuclides, however, future randomized trials should confirm these data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Precision Medicine In Senology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
- Comprehensive Cancer Center, Medical Oncology Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, IT, Faculty of Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.
- Department of Radiotherapy and Radiosurgery, Humanitas Research Center-IRCCS, Rozzano, Milan, Italy.
- Postgraduate School in Radiodiagnostics, Università Degli Studi Di Milano, Milan, Italy.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
- Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Sforza 28, 20122, Milan, Italy.
Förderung
- This research has been partially supported by the Italian Ministry of Health Ricerca Corrente 2025.
Zitieren
APA
Rosenfeld, R., Sganga, S., Badalamenti, M., Mortellaro, S., Scorsetti, M., Garrone, O., Iannantuono, G. M., Chandran, E., Ghidini, M., & Franzese, C. (2025). Combinations of treatments based on radiotherapy or radionuclides to enhance immunotherapy efficacy in advanced prostate cancer: a systematic review. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-025-06245-3
Vancouver
Rosenfeld R, Sganga S, Badalamenti M, Mortellaro S, Scorsetti M, Garrone O, et al. Combinations of treatments based on radiotherapy or radionuclides to enhance immunotherapy efficacy in advanced prostate cancer: a systematic review. Journal of Cancer Research and Clinical Oncology. 2025. doi:10.1007/s00432-025-06245-3
BibTeX
@article{Rosenfeld2025,
author = {Rosenfeld, Roberto and Sganga, Stefano and Badalamenti, Marco and Mortellaro, Sveva and Scorsetti, Marta and Garrone, Ornella and Iannantuono, Giovanni Maria and Chandran, Elias and Ghidini, Michele and Franzese, Ciro},
title = {Combinations of treatments based on radiotherapy or radionuclides to enhance immunotherapy efficacy in advanced prostate cancer: a systematic review},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2025},
doi = {10.1007/s00432-025-06245-3}
}
EUVIMED